Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 Following a Single Oral Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment

NCT02161770 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02161770
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02161770 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Non-randomised, Multicentre, Comparative, Phase I Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD9291 Following a Single Oral Dose to Patients With Advanced Solid Tumours and Normal Hepatic Function or Mild or Moderate Hepatic Impairment
Lead sponsor
AstraZeneca
Phase
Phase 1
Overall status
Completed
Start date
December 22, 2014
Completion date
August 22, 2017
Enrollment
30 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

solid tumours